Clinical trials
Observational Asthma trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Unknown status | 12 |
| Terminated | 3 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 5 |
| Stefania La Grutta, MD | 5 |
| Chiesi Farmaceutici S.p.A. | 3 |
| Istituti Clinici Scientifici Maugeri SpA | 3 |
| Chiesi Italia | 2 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2 |
| Istituto per la Ricerca e l'Innovazione Biomedica | 2 |
| Universita di Verona | 2 |
| University of Catanzaro | 2 |
| University of Pisa | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Asthma | 43 |
| Pulmonary Disease, Chronic Obstructive | 7 |
| Rhinitis, Allergic | 4 |
| Pulmonary Eosinophilia | 2 |
| Anxiety Disorders | 1 |
| Bronchiectasis | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Hypersensitivity | 1 |
| Infections | 1 |
| Inflammation | 1 |
Trials
Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.